Ascendia

  MARKET NEWS

Longeveron Receives Notice of US Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B
First Patient Dosed With LIXTE’s LB-100 & GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
GDMC Secures $21-Million Growth Capital Funding to Expand Global Genetic Medicines Design & Manufacturing Operations
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients With Advanced Cancer Resulting in Recommended Phase 2 Doses
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients With Rheumatoid Arthritis
Evaxion to Develop Tailored Novel Cancer Vaccines Based Upon a New Untapped Source of AI-Discovered Targets

  FEATURED EDITORIAL

  COMPANY PROFILE

MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany. Our ideals have been shaped by our history of more than 350 years – right from the very start. Each of the 13 generations of the Merck family has contributed in its own way, making us what we are today: a leading science and technology company. Our passion for science and technology is what drives our more than 64,000 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live. Thanks to the constant curiosity of our employees, we are making discoveries that can change the landscape of entire industries. For more than 350 years, we have been pushing the boundaries of what is possible, and we will continue to do so in the years to come. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Oxford Biomedica Completes Acquisition of ABL Europe

Oxford Biomedica Completes Acquisition of ABL Europe

The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens….

Repare Therapeutics Announces Achievement of -Million Roche Clinical Milestone Payment

Repare Therapeutics Announces Achievement of $40-Million Roche Clinical Milestone Payment

Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial….

Recipharm, Medspray & Resyca Enter Exclusive License Agreement to Develop Nasally Delivered Drug Products Using Proprietary Soft Mist Technology

Recipharm, Medspray & Resyca Enter Exclusive License Agreement to Develop Nasally Delivered Drug Products Using Proprietary Soft Mist Technology

Recipharm recently announced an exclusive license and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices for single and combination drug products. This collaboration….

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

Ensysce Biosciences, Inc. recently announced receipt of notice from the US FDA that it has granted Breakthrough Therapy Designation (BTD) for PF614-MPAR. A next-generation opioid, PF614-MPAR represents a major….

  WHITEPAPERS & WEBINARS

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

WEBINAR - Enabling Upstream Intensified Bioprocessing

WEBINAR - Enabling Upstream Intensified Bioprocessing

Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

  WHITEPAPERS & WEBINARS

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 7 – Injection Devices
February 14 – Formulation Development